Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Maintenance for R/R ALL Post-Allo-HSCT
NCT06075238Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Sichuan University. Primary endpoints: Progression Free Survival at 2 years and Adverse Events. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06075238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075238.